Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit...

Date First Received: January 8, 2007

Last Updated: July 1, 2008

Verified by: National Institute on Drug Abuse (NIDA), July 2008

Clinical Trial Phase: Phase 2/Phase 3 | Start Date: November 2006

Overall Status: Recruiting

Estimated Enrollment: 120

Brief Summary

Official Title: “Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation”

Condition Keyword(s):

The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: March 2009

Detailed Clinical Trial Description

The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.

Bupropion is an FDA-approved medication for smoking cessation that is believed to provide relief from craving and withdrawal through promotion of two neurotransmitter chemicals, dopamine and noradrenaline. Naltrexone is an FDA-approved medication for the treatment of opiate and alcohol dependence, that appears to function through blocking certain opiate receptors in the brain. It is expected that bupropion + naltrexone will produce higher smoking quit rates than bupropion + placebo.

Bupropion alone is effective in alleviating some nicotine withdrawal complaints and craving for nicotine. However, bupropion does not reduce the rewarding effects of slips to smoking.

Naltrexone alone is not generally effective as a smoking cessation medication, but it does help to reduce the rewarding effects of slips to smoking. Thus, it may help to prevent full relapse to smoking. In addition, naltrexone can help to reduce craving for cigarettes. It is hypothesized that the differing complementary actions of the two drugs will help smokers more than bupropion alone. In addition to examining smoking quit rates, the proposed study will also look at psychological processes that change during smoking cessation including, nicotine withdrawal, nicotine craving, mood, impulsivity, and attention

Intervention(s) in this Clinical Trial

  • Drug: Bupropion
    • Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks. Placebo, 25 mg, q.d., for 7 weeks.
  • Drug: Bupropion + Naltrexone
    • Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks. Naltrexone, 25 mg, q.d., for 7 weeks.

Arms, Groups and Cohorts in this Clinical Trial

  • Active Comparator: 1
    • Bupropion+Placebo
  • Experimental: 2
    • Bupropion+Naltrexone

Outcome Measures for this Clinical Trial

Primary Measures

  • Biochemically-verified point-prevalence abstinence
    • Time Frame: 7, 11, 16, and 30 weeks post-quit
      Safety Issue?: No
  • Likelihood of progression to a relapse (e.g., return to baseline smoking) following a slip at any time in study.
    • Time Frame: At any point following the quit date.
      Safety Issue?: No
  • Treatment completion.
    • Time Frame: Weeks 7 and 30.
      Safety Issue?: No
  • Daily cigarette smoking rate.
    • Time Frame: Weekly
      Safety Issue?: No
  • Frequency and severity of bupropion and naltrexone side effects.
    • Time Frame: Weekly during treatment
      Safety Issue?: Yes

Secondary Measures

  • Attentional bias.
    • Time Frame: Weeks 1, 3, and 7.
      Safety Issue?: No
  • Impulsivity.
    • Time Frame: Weeks 1, 3, and 7.
      Safety Issue?: No
  • Nicotine withdrawal, craving and negative/positive affect.
    • Time Frame: All visits.
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • 18 years and older.
  • Smoked at least 10 cigarettes/day for at least 1 year.
  • English speaking.
  • Females who are of childbearing potential must practice effective contraception and meet the following criteria:
  • Are instructed to avoid pregnancy through 30 days after the last dose of study medication.
  • Have a negative urine pregnancy test at baseline.
  • Agree to use of the birth control methods listed: an oral contraceptive agent, an intrauterine device (IUD), an implantable contraceptive (e.g., Norplant), or an injectable contraceptive (e.g., Depo-Provera) for at least one month prior to entering the study and will continue its use through at least 30 days after the last dose of the study medication. A barrier method of contraception (e.g., condom or diaphragm with spermicide) while participating in the study and 30 days after the last dose of study medication.
  • Willingness to reduce alcohol consumption during study to 2 or fewer standard drinks/day (3 oz. of alcohol or two beers (12 oz.), or two 5 oz. glasses of wine).
  • Willingness to not use illicit drugs during study period including marijuana.

Exclusion Criteria:

  • Concurrent use of tobacco products (other than cigarettes) or nicotine products.
  • Contraindications to use of bupropion (i.e., concurrent use of other forms of bupropion, MAO inhibitors, anti-depressant medication, seizure disorder or any clinical situation that might increase risk for seizures, past head injury, current or prior diagnosis of bulimia or anorexia nervosa; bipolar disorder).
  • Contraindications to use of naltrexone (i.e., past history of opioid abuse or dependence or evidence of opioid use in the past 30 days; significant hepatocellular injury as evidenced by liver enzyme levels over 3 times normal limits).
  • Use of medications whose metabolism or effects may be adversely altered by bupropion or naltrexone. Medications that contraindicate the use of bupropion include theophylline, procarbazine, carbimazole, nialamide, pargyline, toloxatone, iproniazid, and systemic steroids. Medications that contraindicate the use of naltrexone include opioid analgesics and yohimbine.
  • Current use of anti-seizure medications, disulfiram, or any medications that significantly challenge liver functioning.
  • Treatment for drug or alcohol dependence during the last year, or evidence of alcohol abuse so severe that the patient is judged potentially unable to comply with the protocol.
  • Evidence of problem alcohol consumption based on AUDIT.
  • Self-reported use of illicit drugs in the past 90 days (including opioids, but excluding marijuana).
  • Suicidal or homicidal ideation.
  • Current major depression.
  • History of bipolar disorder.
  • Recent (within twelve months) myocardial infarction.
  • Pregnant or lactating or planning pregnancy during treatment period.
  • Having plans to leave the immediate geographical area within 9 months.
  • Unwillingness or inability to given written informed consent.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Clinical Trial Sponsor Information

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Overall Clinical Trial Officials and Contacts

Marc E Mooney, Ph.D. Principal Investigator Univerisity of Minnesota  

Overall Contact: Marc E Mooney, Ph.D. 612-627-1822 moon0078@umn.edu

Related Publications

References

Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995 Sep;56(9):395-401. Review.

Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006 Jul;6(7):965-81. Review.

Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002 Jul 1;67(2):219-23.

Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl). 2000 Jan;148(1):33-40.

Hutchison KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Gnys M, Niaura RS, Sirota AD. Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berl). 1999 Feb;142(2):139-43.

Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction. 1999 Aug;94(8):1227-37.

Krishnan-Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob Res. 2003 Dec;5(6):851-7.

Williams J, Ziedonis DM. Naltrexone-bupropion combination therapy for protracted abstinence dysphoria. Am J Addict. 2003 May-Jun;12(3):270-2. No abstract available.

Epstein AM, King AC. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav. 2004 Jan;77(1):29-37.

King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine Tob Res. 2006 Oct;8(5):671-82.

King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav. 2000 Jul;66(3):563-72.

Brauer LH, Behm FM, Westman EC, Patel P, Rose JE. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Berl). 1999 Apr;143(4):339-46.

Ahmadi J, Ashkani H, Ahmadi M, Ahmadi N. Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. J Subst Abuse Treat. 2003 Apr;24(3):251-5.

Sutherland G, Stapleton JA, Russell MA, Feyerabend C. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berl). 1995 Aug;120(4):418-25.

Wewers ME, Dhatt R, Tejwani GA. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl). 1998 Nov;140(2):185-90.

Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis. 1999;18(1):31-40.

Lerner AG, Oyffe I, Sigal M. Naltrexone-induced reduction of tobacco intake. J Clin Psychiatry. 1998 Jan;59(1):30-1. No abstract available.

David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2001;(3):CD003086. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD003086.

Additional Information

Information obtained from ClinicalTrials.gov on August 28, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00419731

Study ID Number: K01-DA019446-01

ClinicalTrials.gov Identifier: NCT00419731

Health Authority: United States: Federal Government

Tobacco Use Research Center Website

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.